ReNeuron Group plc Posting of Annual Report and Notice of AGM (3171N)

TIDMRENE

RNS Number : 3171N

ReNeuron Group plc

07 August 2017

 
 AIM: RENE   7 August 2017 
 

ReNeuron Group plc

("ReNeuron" or "the Company")

Posting of Annual Report and Accounts and Notice of AGM

ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2017 and the Notice of the 2017 Annual General Meeting ("AGM") have been sent to shareholders and are also available on the Company's website at www.reneuron.com.

ReNeuron's AGM will be held at 10.00am on Wednesday 6 September 2017 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.

ENDS

ENQUIRIES:

 
ReNeuron                                       [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                       [phone] 
Mark Court, Sophie Cowles, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                 [phone] 
 
 

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

 
                             [phone] 
N+1 Singer Advisory LLP      3000 
Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPRMITMBMMBTR

(END) Dow Jones Newswires

August 07, 2017 10:04 ET (14:04 GMT)